PDUFA Date for RP1
Jul 22, 2025, 5:00:00 AM — fda decision
Summary
The FDA has set a PDUFA date of July 22, 2025, for Replimune's RP1, a significant milestone in the regulatory process for this oncolytic immunotherapy.
Company
REPLIMUNE GROUP INC (REPL)NASDAQ — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
replimune.comSimilar Events
FDA PDUFA Action Date for PRGN-2012
The FDA has set an August 2025 PDUFA action date for PRGN-2012, a potential breakthrough therapy for recurrent respiratory papillomatosis (RRP).
fda decisionFDA PDUFA Target Action Date for PRGN-2012
The FDA has set a PDUFA target action date of August 27, 2025, for the review of PRGN-2012, a potential first therapy for recurrent respiratory papillomatosis.
fda decisionPDUFA Date for Subcutaneous Pembrolizumab
The FDA has set a PDUFA date of September 23, 2025, for the review of subcutaneous pembrolizumab, a potential new treatment option in oncology.
fda decisionFDA PDUFA Target Action Date for EMPAVELI®
The FDA has set a PDUFA target action date of July 28, 2025, for the supplemental New Drug Application of EMPAVELI® for treating C3 glomerulopathy and IC-MPGN.
fda decision